MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202611008932 A) filed by Swami Vivekananda Subharti University, Meerut, Uttar Pradesh, on Jan. 29, for 'a composition and a nano-enabled system for ros- and enzyme-triggered release of a thiazolidine-coumarin hybrid for treating multidrug-resistant bacterial infections.'
Inventor(s) include Dr. Aadesh Kumar; and Dr. Nidhi Dhama.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "The present invention provides a dual-trigger nano-enabled antimicrobial composition comprising a thiazolidine-coumarin hybrid scaffold engineered for targeted treatment of multidrug-resistant (MDR) bacterial infections. The hybrid molecule exhibits synergistic inhibition of bacterial DNA gyrase, disruption of cell-wall biosynthesis, interference with efflux pumps, and biofilm destabilization. The hybrid scaffold is encapsulated within a polymeric nanoparticle featuring a reactive oxygen species (ROS)-responsive linker layer and a pathogen-specific enzyme-cleavable coating. This architecture enables infection-selective, sequential release of the active compound only in oxidative and enzyme-rich microenvironments. Optional resistance-prediction modules may assist in optimizing scaffold variants or linker sensitivity but are not essential for therapeutic function. By combining a multi-mechanistic hybrid agent with dual biochemical triggering and enhanced biofilm penetration, the invention delivers localized, potent antimicrobial activity while minimizing systemic toxicity. The disclosed system represents a next-generation therapeutic platform for managing difficult-to-treat and biofilm-associated MDR infections."
Disclaimer: Curated by HT Syndication.
